The effect of a sodium glucose cotransporter 2 inhibitor (SGLT2i) in reducing heart failure
hospitalization in the EMPA‐REG OUTCOMES trial has raised the possibility of using these …

Importance Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF).
Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …

GPR55 is a G protein-coupled receptor recently shown to be activated by certain cannabinoids
and by lysophosphatidylinositol (LPI). However, the physiological role of GPR55 remains …

Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …

Background SGLT2 inhibition decreases albuminuria and reduces the risk of kidney disease
progression in patients with type 2 diabetes. These benefits are unlikely to be mediated by …

Cannabinoid ligands are implicated in many physiological processes and to date two
receptors have been identified. However, a growing body of evidence exists that suggests the …

Results Compared with placebo, reductions in HbA1c with dapagliflozin were 0.6%, 0.5%,
and 0.3%, respectively, for each consecutive lower eGFR subgroup (P value interaction< …

OBJECTIVE Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk for heart
failure hospitalization potentially by inducing sodium excretion, osmotic diuresis, and plasma …

Hyperphosphatemia is common in patients with chronic kidney disease and is increasingly
associated with poor clinical outcomes. Current management of hyperphosphatemia with …

Aims To compare the effects of the sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor
dapagliflozin on estimated (ePV) and measured plasma volume (mPV) and to characterize the …